Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous lorazepam for status epilepticus
2017-000125-13Phase 3
- Sponsor
- Pfizer
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lorazepam in status epilepticus (SE) and seizure, sponsored by Pfizer. Primary endpoint: Responder rate after initial dose.
02
Drugs
lorazepam
03
Conditions
status epilepticus (SE)seizure
Beyond the preview
Go deeper on 2017-000125-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000125-13.